HC Wainwright Has Optimistic Outlook of ACRS FY2026 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued to clients and investors on Monday, March 16th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings per share of ($0.52) for the year, up from their previous forecast of ($0.53). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

Several other brokerages also recently issued reports on ACRS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. Wall Street Zen cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Craig Hallum assumed coverage on shares of Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aclaris Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $9.80.

Aclaris Therapeutics Stock Performance

Aclaris Therapeutics stock opened at $3.74 on Wednesday. The firm has a market capitalization of $451.04 million, a PE ratio of -7.06 and a beta of 0.88. Aclaris Therapeutics has a one year low of $1.05 and a one year high of $4.89. The stock’s 50 day moving average price is $3.39 and its 200 day moving average price is $2.76.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The company had revenue of $1.30 million during the quarter, compared to analyst estimates of $2.07 million. Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Millennium Management LLC grew its position in shares of Aclaris Therapeutics by 111.0% during the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after buying an additional 2,175,101 shares during the last quarter. Kotler Kevin bought a new position in Aclaris Therapeutics in the fourth quarter worth about $5,135,000. Geode Capital Management LLC boosted its stake in Aclaris Therapeutics by 108.4% in the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after acquiring an additional 1,282,042 shares during the period. Ameriprise Financial Inc. bought a new position in shares of Aclaris Therapeutics during the third quarter valued at approximately $2,428,000. Finally, Three Bridge Wealth Advisors LLC bought a new position in shares of Aclaris Therapeutics during the third quarter valued at approximately $1,358,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Trending Headlines about Aclaris Therapeutics

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and kept a $16.00 price target on ACRS — implying large upside from current levels; this analyst support and high target is bullish for investor sentiment and can attract buyers. HC Wainwright Reaffirms Buy
• Positive Sentiment: Aclaris completed patient enrollment in its randomized Phase 2 trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis (109 patients); topline results are expected in Q4 2026 — this advances a key clinical program and provides a clear near-term binary catalyst. Enrollment Completed — GlobeNewswire
• Positive Sentiment: Analyst model tweak: HC Wainwright slightly raised its FY2026 EPS estimate for Aclaris (less negative), reflecting improved visibility into development milestones — small fundamental upgrade that supports the buy rating and target.
• Neutral Sentiment: Market consensus and analyst coverage remain modestly positive overall (consensus “Moderate Buy”); separate notes outline FY2027 earnings expectations — useful for longer-term valuation but not immediate price drivers. Analyst Consensus — AmericanBankingNews
• Neutral Sentiment: Short-interest reports in the recent feed are internally inconsistent (showing zero shares and NaN changes); there’s no clear evidence of a material short-squeeze or large short buildup impacting the stock today.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.